Showing 8641-8650 of 9547 results for "".
- Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancerhttps://practicaldermatology.com/news/immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer/2461468/Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System
- UCB's Bimekizumab Performs Well in Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-hidradenitis-suppurativa/2461464/UCB’s bimekizumab may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa, according to topline results from two Phase 3 studies, BE HEARD I and BE HEARD II. The positive results from these two studies will form the basis of global reg
- WHO Recommends New Name for Monkeypoxhttps://practicaldermatology.com/news/who-recommends-new-name-for-monkeypox/2461448/The World Health Organization (WHO) will begin using “mpox” as a synonym for monkeypox. Both names will be used simultaneously for one year while “monkeypox” is phased out. When the outbreak of monkeypox expanded earlier this year, racist and
- Case Study: Ulcer at Corner of Mouth May Be First Sign of Monkeypox Virushttps://practicaldermatology.com/news/case-study-ulcer-at-corner-of-mouth-may-be-first-sign-of-monkeypox-virus/2461429/Recent infection with monkeypox virus may initially present with an ulcer at the corner of the mouth, according to a case study of a 51-year-old HIV-positive patient published in Deutsches Ärzteblatt international</
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- Potential Hair Growth Breakthrough: Researchers Grow Mature Hair Follicles in Labhttps://practicaldermatology.com/news/potential-hair-growth-breakthrough-researchers-grow-mature-hair-follicles-in-lab/2461398/Japanese researchers have successfully grown hair follicles in the lab. The team created a system that produces fully mature hair follicles as well as hair as long as 3 millimeters after a few weeks' growth. The in vitro hair follicle model adds to the understanding of ha
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB
- La Roche-Posay and the Women's Dermatologic Society Partner for Inaugural Diversity in Dermatology Fellowship at Howard Universityhttps://practicaldermatology.com/news/la-roche-posay-and-the-womens-dermatologic-society-partner-for-inaugural-diversity-in-dermatology-fellowship-at-howard-university/2461383/La Roche-Posay is partnering with the Women's Dermatologic Society (WDS) to sponsor a Fellowship in the Department of Dermatology at Howard University's College of Medicine for UIM medical students. The fellowship was created to support UIM candidates who are seeking additional clinical o
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i